- Our Story
- Our Products
- Our Science
- Our People & Citizenship
-
Investors
- Reports and Filings
- Presentations & Earnings Calls
-
Shares
- Share Price
- Stock Updates
- Equity & Dividend History
- Unpaid & Unclaimed Dividend
- Analyst Coverage
- Shareholding Pattern
- Share Transfer Information
- Buyback
- Details of Shares for transfer to IEPF May 2018
- Notice pursuant to IEPF Rules, May 2018
- Details of Shares for transfer to IEPF May 2019
- Notice Pursuant to IEPF Rules, May 2019
- Details of Shares for transfer to IEPF May 2020
- Notice pursuant to IEPF Rules, May 2020
- Details of Shares for transfer to IEPF May 2021
- Notice pursuant to IEPF Rules, May 2021
- Governance
- Investor Services
-
ESG profile
- Media
- Partners
- Contact Us
Press Releases
Dec
- Dr. Reddy's Laboratories announces the launch of Sevelamer Carbonate for Oral Suspension in the U.S. Market
- Dr. Reddy's Laboratories launches Aspirin and Extended-Release Dipyridamole Capsules in the U.S. Market
- Dr. Reddy’s announces the launch of over-the-counter store brand equivalent of Prilosec OTC® (Omeprazole Delayed-Release) Tablets, 20 mg in the U.S. Market
Nov
Oct
- Dr. Reddy's Laboratories announces the launch of Atomoxetine Capsules, USP in the U.S. Market
- Dr. Reddy’s Q2 & H1 FY19 Financial Results
- Dr. Reddy's Laboratories receives approval for Aspirin and Extended-Release Dipyridamole Capsules in the U.S. Market
- Dr. Reddy's Laboratories announces the sale of its API manufacturing business unit in Jeedimetla, Hyderabad
- Dr. Reddy's Laboratories announces the launch of Colesevelam Hydrochloride Tablets in the U.S. Market
- Dr. Reddy's Laboratories announces the sale of Cloderm® (clocortolone pivalate) Cream, 0.1% Franchise to EPI Health, LLC
- Dr. Reddy's Laboratories announces the sale of its antibiotic manufacturing site and its related assets in Bristol, Tennessee
- Dr. Reddy's Laboratories announces the launch of Imatinib Mesylate Tablets, USP in the U.S. Market
- Dr. Reddy’s Laboratories announces that it has regained worldwide rights to DFA-02
Jul
- Dr. Reddy’s Q1 FY19 Financial Results
- Dr. Reddy's Laboratories announces the launch of Hervycta® (trastuzumab biosimilar) in India
- Dr. Reddy’s announces the launch of Esomeprazole Magnesium Delayed-Release Capsules USP, 20 mg in the U.S. Market
- Dr. Reddy's Laboratories announces the launch of Hydroxychloroquine Sulfate Tablets, USP in the U.S. Market
- Dr. Reddy’s and UCB India enter into an agreement to co-promote and distribute Briviact® for the treatment of Epilepsy in India
- Dr. Reddy’s announces the launch of Repatha™ in India
Jun
- Dr. Reddy's Laboratories announces the launch of Levetiracetam in Sodium Chloride Injection in the U.S. Market
- Dr. Reddy’s Laboratories Limited announces filing of Annual Report on Form 20-F
- Dr. Reddy's Laboratories defends its right to launch Buprenorphine and Naloxone Sublingual Film in the U.S. Market
- Dr. Reddy's Laboratories announces USFDA final approval and launch of Buprenorphine and Naloxone Sublingual Film in the U.S. Market
- Dr. Reddy's Laboratories Limited to present at the Jefferies 2018 Healthcare Conference
Mar
